Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Dermata Therapeutics Enrolls 50% Of Patients In Pivotal Phase 3 STAR-1 Study For DMT310, A Novel Once-Weekly Topical Acne Treatment; Topline Results Expected In Q1 2025; Potential To Be First Once-Weekly Topical Product For Moderate-To-Severe Acne Treatment

Author: Benzinga Newsdesk | July 17, 2024 09:07am

Posted In: DRMA